Santhera Pharmaceuticals Holding AG | 0.64 / 0.00% |
Date/Time | 03/29 / 17:11 |
Chg. / Chg.(%) | 0.00 / 0.00% |
Bid | - |
Ask | - |
Open | 0.62 |
Previous Close | 0.64 |
High | 0.65 |
Low | 0.62 |
Volume [CHF] | 5,495.01 |
Volume [Units] | 8,643 |
Price fixings | 7 |
ISIN | CH0027148649 |
Security | SANN/Z |
Exchange | Cboe Europe CXE |
Type | Stock |
Other Exchanges
Exchange | Last | Volume | |
---|---|---|---|
SIX Swiss Ex.. | 0.6210 | ![]() |
246,496 |
Cboe Europe .. | 0.64 | ![]() |
8,643 |
Cboe Europe .. | 0.62 | ![]() |
5,940 |
Lang & Schwa.. | 0.61 | ![]() |
|
London Domes.. | 0.6400 | 7,330 | |
Turquoise | 0.63 | ![]() |
2,859 |
Nasdaq Other.. | 1.2000 | 120 | |
München | 13.700 | 0 | |
Berlin | 13.720 | 0 | |
Frankfurt | 13.6400 | 0 |
News
- Santhera and ReveraGen Start Rolling NDA Submission to the FDA for Vamorolone for the Treatment of Duchenne Muscular Dystrophy
03/29/2022 / 07:00 - GlobeNewswire - Santhera and ReveraGen to Present Efficacy and Safety Data with Vamorolone at 2022 Muscular Dystrophy Association Conference
03/15/2022 / 07:05 - GlobeNewswire - Santhera Completes Ordinary Capital Increase to Create Treasury Shares for Future Financing
03/15/2022 / 07:00 - GlobeNewswire - Santhera Announces Preliminary 2021 Financial Results and Increases Issued Share Capital to Create Treasury Shares for Future Financing
03/11/2022 / 07:00 - GlobeNewswire - Santhera Signs Gene Therapy Agreement with SEAL Therapeutics
02/28/2022 / 07:00 - GlobeNewswire